SXTP 60 Degrees Pharmaceuticals Inc.: Enterprise Value-to-Revenue Multiple

60 Degrees Pharmaceuticals - graphic logo of issuer SXTP

The EV-to-sales ratio on the chart correlates with geopolitical instability in the tropics, which impacts drug demand and logistics. The value of 11489.13 shows the latest metric reading, helping to avoid a value trap. Meanwhile, 60 Degrees Pharmaceuticals (SXTP) is focusing on Arakoda bioengineering to achieve niche leadership, although a lack of sales and rising laboratory costs limit the business's scalability.

SXTP: 60 Degrees Pharmaceuticals Inc. Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for 60 Degrees Pharmaceuticals, Inc. (SXTP)

Fundamental company valuation:60 Degrees Pharmaceuticals Inc., SXTP
Manufactured products of 60degreespharma.com

This metric determines the business value net of debt per unit of revenue, allowing for an assessment of the asset's fundamental attractiveness regardless of its financing structure. By analyzing the EV/Sales multiple of 60 Degrees Pharmaceuticals (SXTP) on the GURU.Markets platform, an investor evaluates the capitalization efficiency of 60 Degrees Pharmaceuticals sales, taking into account its commitment to green standards in the development of anti-infective drugs and the optimization of bioethical costs.